Navigation Links
NOVAVAX Featured at Clinton Global Initiative 2008 Annual Meeting
Date:9/29/2008

Company recognized for pursuit of cost-effective and rapidly deployed

vaccine solution for avian and seasonal flu

ROCKVILLE, Md., Sept. 29 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) announced today its recognition at the annual meeting of the Clinton Global Initiative ("CGI") for developing affordable methods of producing an H5N1 avian influenza vaccine and a seasonal influenza vaccine using the company's proprietary recombinant virus-like particles ("VLPs"). As one of the organizations chosen to attend the CGI this year, Novavax is working to create novel vaccines and manufacturing solutions for producing avian and seasonal influenza vaccines with portable equipment that can be deployed worldwide.

The company believes its vaccine initiatives have the potential to impact millions of people affected by infectious diseases each year by creating novel vaccines that can be produced in a cost effective and timely manner within the same scalable manufacturing platform worldwide.

Novavax's manufacturing process makes it possible to rapidly produce an influenza vaccine that contains strains that are an exact genetic match to the strains circulating in the country or region causing influenza disease. Novavax's influenza VLPs are produced through recombinant technology in insect cell culture, utilizing a manufacturing process that will consist entirely of disposable, ready-to-use equipment. Current yields are 7 to 10 times higher than those of traditional egg-based or mammalian cell culture manufacturing. Because the Novavax process involves recombinant technology and does not require a live influenza virus, a matched vaccine for avian or seasonal influenza can be manufactured within 12 weeks of identification by the Centers for Disease Control and Prevention, which is approximately half the time required to manufacture egg-based vaccines.

Novavax has developed a VLP based vaccine candidate against H5N1 avian influenza that has completed a Phase IIa clinical trial. The study demonstrated that the VLP vaccine is well tolerated and immunogenic and can be produced rapidly to supply vaccine against an emerging pandemic strain. The company has also commenced a Phase II trial in healthy adults for its seasonal influenza vaccine candidate.

About the Clinton Global Initiative (CGI)

Established in 2005 as a project of the non-partisan William J. Clinton Foundation, the Clinton Global Initiative (CGI) convenes global leaders to devise and implement innovative solutions to some of the world's most pressing challenges. Since 2005, CGI members have made nearly 1,000 Commitments to Action valued at upwards of $30 billion to improve more than 200 million lives in over 150 countries around the world. Through past Annual Meetings, CGI has brought together more than 80 current and former heads of state, hundreds of top CEOs and nonprofit leaders, major philanthropists, and 10 of the last 16 Nobel Peace Prize laureates.

About Novavax

Novavax, Inc. is a clinical stage biotechnology company, creating novel vaccines to address a broad range of infectious diseases worldwide using advanced proprietary virus-like particle (VLP) technology. The Company produces these VLP based, potent, recombinant vaccines utilizing new, and efficient manufacturing approaches. Additional information about Novavax is available at http://www.novavax.com and in the Company's various filings with the Securities and Exchange Commission.

Forward-Looking Statement

Statements herein relating to future development results and performance, conditions or strategies and other matters, including expectations regarding product and clinical developments, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Novavax cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks relating to the early stage of Novavax's product candidates under development; current results may not be predictive of future pandemic results, results of our seasonal influenza vaccine or any other vaccine that we may develop; further testing is required before regulatory approval can be applied for and the FDA may not approve a vaccine even if further trial results are similar to those disclosed previously by the company; uncertainties relating to clinical trials; dependence on the efforts of third parties; competition for clinical resources and patient enrollment from drug candidates in development by other companies with greater resources and visibility; and risks that we may lack the financial resources and access to capital to fund our operations including further clinical trials. Further information on the factors and risks that could affect Novavax's business, financial conditions and results of operations, is contained in Novavax's filings with the U.S. Securities and Exchange Commission, which are available at http://www.sec.gov. These forward-looking statements speak only as of the date of this press release, and Novavax assumes no duty to update forward-looking statements.


'/>"/>
SOURCE Novavax, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Novavax CEO to Present at ACUMENBioFins 9th Annual Healthcare Conference
2. Novavax Reports Third Quarter 2007 Financial Results and Progress with Vaccine Development Programs
3. GE Healthcare and Novavax Establish Collaboration To Develop and Market Pandemic Influenza Solution
4. Novavax Announces Preclinical Results for Seasonal Influenza Vaccine Program
5. Novavax Announces Favorable Interim Results from Human Clinical Trial for Its Pandemic Influenza Vaccine Program
6. Novavax Reports Fourth Quarter and 2007 Year-End Financial Results
7. Novavax Reports Positive Results from Preclinical Studies of its VLP-based Trivalent Seasonal Influenza Vaccine Candidate
8. Novavax Completes Enrollment in Phase I/IIa Pandemic Influenza Vaccine Clinical Trial
9. Novavax Announces Proprietary Method to Create SARS Vaccine and Renewal of NIH Funding for SARS Vaccine Development
10. Novavax to Present Phase I/IIa Trial Data Results in an Investor Conference Call on August 26, 2008
11. Novavax Announces Favorable Results from Phase I/IIa Pandemic Influenza Vaccine Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2020)... ... July 01, 2020 , ... Stratodesk today ... OS is available on NComputing devices. Thanks to fantastic new growth and stellar ... formed a new partnership that will make the full Stratodesk NoTouch OS branded ...
(Date:6/25/2020)... ... 25, 2020 , ... R3 Medical Training announced today it is now enrolling ... locations. The first course is August 6-7, 2020 in San Diego and the second ... a Virtual Live Stream option. , The two day agenda for each course is ...
(Date:6/25/2020)... ... June 25, 2020 , ... The Heritage Downtown Active Senior Living Apartment ... COVID-19. With over 100,000 positive cases of the coronavirus in the United States to ... at The Heritage Downtown, their family members, as well as the Walnut Creek community. ...
Breaking Medicine Technology:
(Date:6/23/2020)... CHICAGO (PRWEB) , ... June 23, 2020 , ... Oak ... on Medicare, today announced further plans for nationwide expansion in 2020 with the company’s ... company plans to open two locations in Brooklyn, N.Y., and a new center in ...
(Date:6/23/2020)... VANCOUVER, British Columbia (PRWEB) , ... June 23, 2020 , ... ... today that Dr. Mike Hart has been named as the President of ... years of experience in plant based therapy, including owning and operating his own family ...
(Date:6/23/2020)... ... June 22, 2020 , ... In its latest ... and forecasts for the market for tests tied to therapeutic selection or effectiveness. ... in hospitals, as well as pharmaceutical companies serving them to determine recent market trends. ...
(Date:6/23/2020)... ... June 22, 2020 , ... A June 1 article ... light of the country slowly opening back up while adjusting to new rules regarding ... of the face that aren’t covered such as eyelids, lashes, and brows. Beverly Hills ...
(Date:6/23/2020)... Ga. (PRWEB) , ... June 22, 2020 , ... The ... is seeing its limelight. A May 2020 Frost & Sullivan survey predicts ... than ever to using phone and Internet services to receive care. ...
Breaking Medicine News(10 mins):